Dr. Christopher Chengelis is a highly experienced toxicologist with over 40 years of leadership across pharmaceutical, biotechnology, and chemical safety programs. He advises clients on preclinical development strategy, regulatory toxicology, and risk assessment, supporting IND/NDA submissions, GRAS notifications, and complex safety evaluations for novel therapeutics and drug delivery systems. His expertise spans dermal and inhalation toxicology, cardiovascular and reproductive safety, immunotoxicity, and mechanistic toxicology.

Dr. Chengelis previously served as Chief Scientific Officer at WIL Research Laboratories (now part of Charles River Laboratories), where he led global toxicology operations, directed hundreds of preclinical studies, and scaled the General Toxicology Division to over 300 professionals. He has extensive experience supporting oncology, rare disease, and combination therapy programs, as well as advising CROs and investors on due diligence and development strategy.

He holds a Ph.D. in Pharmacology from the University of Illinois Medical Center and is a Diplomate of the American Board of Toxicology (D.A.B.T.). Dr. Chengelis is a past president of the American College of Toxicology and an emeritus member of the Society of Toxicology.